Green Cross Holdings (A005250) Stock Overview
Operates as a biotechnology company. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 2/6 |
A005250 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Green Cross Holdings Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩14,050.00 |
| 52 Week High | ₩17,700.00 |
| 52 Week Low | ₩12,000.00 |
| Beta | 0.56 |
| 1 Month Change | -8.47% |
| 3 Month Change | -14.07% |
| 1 Year Change | -0.21% |
| 3 Year Change | -9.53% |
| 5 Year Change | -59.63% |
| Change since IPO | 752.49% |
Recent News & Updates
Green Cross Holdings (KRX:005250) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Nov 23
Green Cross Holdings' (KRX:005250) Strong Earnings Are Of Good Quality
Mar 25Recent updates
Green Cross Holdings (KRX:005250) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Nov 23Green Cross Holdings' (KRX:005250) Strong Earnings Are Of Good Quality
Mar 25Green Cross Holdings Corporation's (KRX:005250) Price Is Right But Growth Is Lacking
Jan 17Is Green Cross Holdings (KRX:005250) Using Debt Sensibly?
Dec 17Is Green Cross Holdings (KRX:005250) Using Debt Sensibly?
Aug 09Know This Before Buying Green Cross Holdings Corporation (KRX:005250) For Its Dividend
Apr 28Is Now The Time To Put Green Cross Holdings (KRX:005250) On Your Watchlist?
Mar 21Green Cross Holdings (KRX:005250) Seems To Be Using A Lot Of Debt
Mar 01If You Had Bought Green Cross Holdings (KRX:005250) Stock A Year Ago, You Could Pocket A 106% Gain Today
Feb 12Here's What Green Cross Holdings Corporation's (KRX:005250) Shareholder Ownership Structure Looks Like
Jan 28We're Not So Sure You Should Rely on Green Cross Holdings's (KRX:005250) Statutory Earnings
Jan 12
Green Cross Holdings Corporation (KRX:005250) Investors Should Think About This Before Buying It For Its Dividend
Dec 28Green Cross Holdings Corporation's (KRX:005250) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Dec 13Green Cross Holdings (KRX:005250) Use Of Debt Could Be Considered Risky
Nov 28Optimistic Investors Push Green Cross Holdings Corporation (KRX:005250) Shares Up 63% But Growth Is Lacking
Nov 28Shareholder Returns
| A005250 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -11.8% | -6.6% | -9.8% |
| 1Y | -0.2% | 44.1% | 110.4% |
Return vs Industry: A005250 underperformed the KR Biotechs industry which returned 36.2% over the past year.
Return vs Market: A005250 underperformed the KR Market which returned 108.4% over the past year.
Price Volatility
| A005250 volatility | |
|---|---|
| A005250 Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in KR Market | 14.9% |
| 10% least volatile stocks in KR Market | 4.0% |
Stable Share Price: A005250 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A005250's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | 141 | Yong-Jun Huh | www.gcbiopharma.com |
Green Cross Holdings Corporation operates as a biotechnology company. The company provides prescription drugs and over the counter drugs; aseptic fill and finish services for drug manufacturing; and pharmaceutical logistics services. It also researches and develops plasma derivatives for von Willebrand disease and primary immunodeficiency; vaccines for mRNA flu, anthrax, tetanus, diphtheria, pertussis, tuberculosis, and varicella; recombinant treatments for acquired thrombotic thrombocytopenic purpura, fabry, hemophilia, hunterase, colon cancer, and hunter syndrome; and small molecules for gangliosidosis andalagille’s syndrome.
Green Cross Holdings Corporation Fundamentals Summary
| A005250 fundamental statistics | |
|---|---|
| Market cap | ₩640.17b |
| Earnings (TTM) | ₩127.58b |
| Revenue (TTM) | ₩2.40t |
Is A005250 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A005250 income statement (TTM) | |
|---|---|
| Revenue | ₩2.40t |
| Cost of Revenue | ₩1.74t |
| Gross Profit | ₩657.93b |
| Other Expenses | ₩530.36b |
| Earnings | ₩127.58b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.81k |
| Gross Margin | 27.45% |
| Net Profit Margin | 5.32% |
| Debt/Equity Ratio | 77.2% |
How did A005250 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/06 17:01 |
| End of Day Share Price | 2026/03/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Green Cross Holdings Corporation is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sang-Hun Lee | iM Securities |
| Jae Hyun Kwon | Mirae Asset Securities Co., Ltd. |